Stride Analyst Ratings
Stride Analyst Ratings
Morgan Stanley Raises Price Target on Stride to $70 From $65, Cites 'Solid Quarter,' Keeps Equalweight Rating
Stride Analyst Ratings
Buy Rating Justified for Stride Inc. on Strong Market Position and Growth Prospects in Virtual Education
Stride Analyst Ratings
Stride Analyst Ratings
Stride (LRN) Outpaces Expectations: A Comprehensive Buy Rating Justification
Stride Analyst Ratings
Stride, Inc. Outperforms With Strong Financial Results and Undervalued Stock: A Buy Rating Reaffirmed
Hold Rating and Lowered Price Target for Reneo Pharmaceuticals Following STRIDE Study Setback and Operational Challenges
What 6 Analyst Ratings Have To Say About Stride
Stride Analyst Ratings
BMO Capital Adjusts Stride's Price Target to $67 From $57, Maintains Outperform Rating
The Latest Analyst Ratings for Stride
Morgan Stanley Maintains Equal-Weight on Stride, Raises Price Target to $60
Stride Analyst Ratings
BMO Capital Maintains Outperform on Stride, Raises Price Target to $57
Stride Analyst Ratings
Stride's Positive Financial Performance and Growth Prospects Lead to Buy Rating